Enfusion Stock Today
| ENFN Stock | USD 11.07 0.11 1.00% |
Performance11 of 100
| Odds Of DistressLess than 1
|
Enfusion is selling at 11.07 as of the 17th of January 2025; that is 1.00 percent increase since the beginning of the trading day. The stock's open price was 10.96. Enfusion has a very small chance of experiencing financial distress in the next few years and had a good performance during the last 90 days. The performance scores are derived for the period starting the 18th of December 2024 and ending today, the 17th of January 2025. Click here to learn more.
Business Domain Software & Services | IPO Date 21st of October 2021 | Category Technology | Classification Information Technology |
Enfusion, Inc. provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. Enfusion Inc. was incorporated in 2021 and is headquartered in Chicago, Illinois. Enfusion Inc operates under SoftwareApplication classification in the United States and is traded on New York Stock Exchange. The company has 94.77 M outstanding shares of which 556.5 K shares are currently shorted by private and institutional investors with about 1.12 trading days to cover. More on Enfusion
Moving together with Enfusion Stock
| 0.65 | DJCO | Daily Journal Corp | PairCorr |
| 0.82 | AI | C3 Ai Inc | PairCorr |
| 0.84 | AZ | A2Z Smart Technologies | PairCorr |
| 0.67 | BL | Blackline | PairCorr |
Moving against Enfusion Stock
Enfusion Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Business Concentration | Application Software, Software - Application, Information Technology, NYSE Composite, Information Technology, Software, Software—Application, Technology (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsEnfusion can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Enfusion's financial leverage. It provides some insight into what part of Enfusion's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Enfusion (ENFN) is traded on New York Stock Exchange in USA. It is located in 125 South Clark Street, Chicago, IL, United States, 60603 and employs 1,102 people. Enfusion is listed under Application Software category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.04 B. Enfusion conducts business under Software sector and is part of Information Technology industry. The entity has 94.77 M outstanding shares of which 556.5 K shares are currently shorted by private and institutional investors with about 1.12 trading days to cover.
Enfusion currently holds about 56.56 M in cash with 25.63 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.84.
Check Enfusion Probability Of Bankruptcy
Ownership AllocationEnfusion holds a total of 94.77 Million outstanding shares. The majority of Enfusion outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Enfusion to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Enfusion. Please pay attention to any change in the institutional holdings of Enfusion as this could imply that something significant has changed or is about to change at the company. Also note that almost one million seven hundred ninety-one thousand one hundred fourty-four invesors are currently shorting Enfusion expressing very little confidence in its future performance.
Check Enfusion Ownership Details
Enfusion Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| T. Rowe Price Investment Management,inc. | 2024-09-30 | 1.3 M | |
| Geode Capital Management, Llc | 2024-09-30 | 1 M | |
| Wellington Management Company Llp | 2024-09-30 | 976.3 K | |
| State Street Corp | 2024-09-30 | 952.9 K | |
| Dimensional Fund Advisors, Inc. | 2024-09-30 | 688.5 K | |
| Impax Asset Management Group Plc | 2024-09-30 | 676.9 K | |
| Bank Of America Corp | 2024-09-30 | 598.8 K | |
| Citadel Advisors Llc | 2024-09-30 | 473.1 K | |
| Scalar Gauge Management, Llc | 2024-09-30 | 453.5 K | |
| Iconiq Capital, Llc | 2024-09-30 | 14 M | |
| Brown Capital Management, Llc | 2024-09-30 | 7.2 M |
Enfusion Historical Income Statement
Enfusion Stock Against Markets
Enfusion Corporate Management
| Stephen Dorton | Chief Officer | Profile | |
| Michael Berry | Chief Officer | Profile | |
| Lorelei Skillman | Chief Officer | Profile | |
| Stephen Malherbe | Managing Partner | Profile | |
| Oleg Movchan | Interim Director | Profile | |
| Matthew Campobasso | General Secretary | Profile | |
| Bronwen Bastone | Chief Officer | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enfusion. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census. To learn how to invest in Enfusion Stock, please use our How to Invest in Enfusion guide.You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Is Application Software space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enfusion. If investors know Enfusion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enfusion listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.27) | Earnings Share 0.04 | Revenue Per Share | Quarterly Revenue Growth 0.154 | Return On Assets |
The market value of Enfusion is measured differently than its book value, which is the value of Enfusion that is recorded on the company's balance sheet. Investors also form their own opinion of Enfusion's value that differs from its market value or its book value, called intrinsic value, which is Enfusion's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enfusion's market value can be influenced by many factors that don't directly affect Enfusion's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enfusion's value and its price as these two are different measures arrived at by different means. Investors typically determine if Enfusion is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enfusion's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.